Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Ep...(at EURO 342 million due to the ongoingin...),Health

The efficacy results from the EORTC (European Organization for Research and Treatment of Cancer) EPOC Intergroup study were published in the Lancet in March. These results showed that in eligible patients, Eloxatin(R) in combination with 5-fluorouracil/leucovorin (a chemotherapy regimen called FOLFOX4) significantly improved progression-free survival compared to surgery alone when given perioperatively (before and after surgery) to colorectal cancer patients with initially resectable liver metastases.

Net sales of Tritace(R), affected by competition from generics in Canada and Europe, fell by 34.9% to EURO 138 million.

Net sales of Acomplia(R) were EURO 22 million.

In March, the National Institute for Health and Clinical Excellence (NICE) -- the organization responsible for providing national guidance on the prevention and treatment of ill health in England and Wales -- recommended the use of Acomplia(R) within its licensed indications as an adjunct to diet and exercise for adults who are obese or overweight and who have had an inadequate response to, are intolerant of, or are contraindicated to other anti-obesity agents previously reviewed by NICE.

Xyzal(R), a new prescription oral antihistamine, was launched by sanofi-aventis and UCB in the United States at the start of October 2007. The product reported 2008 first-quarter sales of EURO 18 million. On February 19, UCB and sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) had approved Xyzal(R) oral solution for the relief of seasonal and year round allergies and chronic idiopathic urticaria.

Worldwide presence of Plavix(R) / Iscover(R)

EURO million Q1 2008 Change on a comparable basis

Europe
'/>"/>